Deramciclane

Deramciclane (EGIS-3886) is a drug which acts as an antagonist at the 5-HT2A receptor, as an inverse agonist at the 5-HT2C receptor, and as a GABA reuptake inhibitor.

In 2003 Orion Pharma of Finland and partner Pharmacia discontinued the development of deramciclane for generalized anxiety disorder, owing to a lack of efficacy in the combined results of the Phase III trials of the agent.